Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of PanCytoVir Oral Suspension in Healthy Adults
NCT06025318Phase 1Completed
- Sponsor
- TrippBio
- Start
- Sep 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of probenecid in coronavirus disease 2019 (COVID-19), influenza and respiratory syncytial virus infection (RSV) (2 arms), sponsored by TrippBio. Primary endpoints: Maximum Plasma Concentration at 7 days and Area Under the Curve at 7 days. Started Sep 2024; status: completed.
02
Drugs
probenecid
03
Conditions
coronavirus disease 2019 (COVID-19)influenzarespiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06025318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06025318.